| 1 |
Oncogenic BRAF harboring melanoma cell line response to BRAF inhibition
|
Homo sapiens
|
Homo sapiens
|
| 2 |
PGC1alpha depletion effect on melanoma cell line
|
Homo sapiens
|
Homo sapiens
|
| 3 |
CD133 depletion effect on metastatic melanoma cell line
|
Homo sapiens
|
Homo sapiens
|
| 4 |
Dual roles of RNF2 in melanoma progression [expression]
|
Homo sapiens
|
Homo sapiens
|
| 5 |
Shp2 transcriptome in melanoma
|
Homo sapiens
|
Homo sapiens
|
| 6 |
TGFβ1 treatment of A2058 melanoma cells
|
Homo sapiens
|
Homo sapiens
|
| 7 |
siRNA induced silencing of CITED1 in HT144 human melanoma cells
|
Homo sapiens
|
Homo sapiens
|
| 8 |
Transcriptome data from human malanoma A375 cells stably expressing MAP4K5 shRNA.
|
Homo sapiens
|
Homo sapiens
|
| 9 |
Functional analysis of ABCB5 in melanoma cells
|
Homo sapiens
|
Homo sapiens
|
| 10 |
Analysis of global changes in gene expression induced by human polynucleotide phosphorylase (hPNPaseold-35)
|
Homo sapiens
|
Homo sapiens
|
| 11 |
Synergistic anti-tumor activity by association of MEK and PI3K/mTOR blockade with TRAIL in human melanoma
|
Homo sapiens
|
Homo sapiens
|
| 12 |
Synergistic anti-tumor activity by association of MEK and PI3K/mTOR blockade with TRAIL in human melanoma
|
Homo sapiens
|
Homo sapiens
|
| 13 |
Oncogenic BRAF harboring melanoma cell line response to BRAF inhibition
|
Homo sapiens
|
Homo sapiens
|
| 14 |
SOX9 overexpression in melanoma
|
Homo sapiens
|
Homo sapiens
|
| 15 |
Synergistic anti-tumor activity by association of MEK and PI3K/mTOR blockade with TRAIL in human melanoma
|
Homo sapiens
|
Homo sapiens
|
| 16 |
Molecular changes induced by melanoma cell conditioned medium (MCM) in HUVEC cells.
|
Homo sapiens
|
Homo sapiens
|
| 17 |
Gene expression profile in melanomas from Pdk1-inactivated BrafV600E::Pten-/- mice
|
Mus musculus
|
Mus musculus
|
| 18 |
The role of SOX10 in human melanoma
|
Homo sapiens
|
Homo sapiens
|
| 19 |
The role of SOX10 in human melanoma
|
Homo sapiens
|
Homo sapiens
|
| 20 |
Expression data from Control, Uninfected and BRAF infected cells
|
Homo sapiens
|
Homo sapiens
|
| 21 |
EWI-2 regulates melanoma growth and lung metastasis in a TGF-β1-dependent manner
|
Homo sapiens
|
Homo sapiens
|
| 22 |
Gene expression profiling of enforced HOXA1 expression in melanoma cell line
|
Homo sapiens
|
Homo sapiens
|
| 23 |
Gene expression profiling of enforced HOXA1 expression in melanoma cell line (SkMel30)
|
Homo sapiens
|
Homo sapiens
|
| 24 |
Expression data from mouse B16-F10 cells exposed to hypoxic conditions in vitro.
|
Mus musculus
|
Mus musculus
|
| 25 |
Expression data from mouse B16-F10 cells exposed to hypoxic conditions in vitro.
|
Mus musculus
|
Mus musculus
|
| 26 |
Analysis of A375 and A375 clones that acquired resistance to GSK2118436 after treatment with GSK2118436 (GSK436), GSK1120212 (GSK212), or the combination of GSK2118436 and GSK1120212 for 24 hour
|
Homo sapiens
|
Homo sapiens
|
| 27 |
Analysis of A375 and A375 clones that acquired resistance to GSK2118436 after treatment with GSK2118436 (GSK436), GSK1120212 (GSK212), or the combination of GSK2118436 and GSK1120212 for 24 hour
|
Homo sapiens
|
Homo sapiens
|
| 28 |
Analysis of A375 and A375 clones that acquired resistance to GSK2118436 after treatment with GSK2118436 (GSK436), GSK1120212 (GSK212), or the combination of GSK2118436 and GSK1120212 for 24 hour
|
Homo sapiens
|
Homo sapiens
|
| 29 |
Analysis of A375 and A375 clones that acquired resistance to GSK2118436 after treatment with GSK2118436 (GSK436), GSK1120212 (GSK212), or the combination of GSK2118436 and GSK1120212 for 24 hour
|
Homo sapiens
|
Homo sapiens
|
| 30 |
Gene expression profiles of Wnt-1 overexpressing melanoma
|
Homo sapiens
|
Homo sapiens
|
| 31 |
Analysis of A375 and A375 clones that acquired resistance to GSK2118436 after treatment with GSK2118436 (GSK436), GSK1120212 (GSK212), or the combination of GSK2118436 and GSK1120212 for 24 hour
|
Homo sapiens
|
Homo sapiens
|
| 32 |
Gene expression profiles of Wnt-1 overexpressing melanoma
|
Homo sapiens
|
Homo sapiens
|
| 33 |
Analysis of A375 and A375 clones that acquired resistance to GSK2118436 after treatment with GSK2118436 (GSK436), GSK1120212 (GSK212), or the combination of GSK2118436 and GSK1120212 for 24 hour
|
Homo sapiens
|
Homo sapiens
|
| 34 |
Analysis of A375 and A375 clones that acquired resistance to GSK2118436 after treatment with GSK2118436 (GSK436), GSK1120212 (GSK212), or the combination of GSK2118436 and GSK1120212 for 24 hour
|
Homo sapiens
|
Homo sapiens
|
| 35 |
Expression data from mouse B16-F10 cells exposed to hypoxic conditions in vitro.
|
Mus musculus
|
Mus musculus
|
| 36 |
Expression data from mouse B16-F10 cells exposed to hypoxic conditions in vitro.
|
Mus musculus
|
Mus musculus
|
| 37 |
Role of Apollon in human melanoma resistance to anti-tumor agents that activate the intrinsic or the extrinsic apoptosis pathways
|
Homo sapiens
|
Homo sapiens
|
| 38 |
Inhibitor of NEDD8-activating enzyme MLN4924 effect on melanoma cell line
|
Homo sapiens
|
Homo sapiens
|
| 39 |
Expression data from mouse B16-F10 cells treated with heat shock (HS), Lipofectamine 2000 (LA), and benzyl alcohol (BA)
|
Mus musculus
|
Mus musculus
|
| 40 |
Expression data from mouse B16-F10 cells treated with heat shock (HS), Lipofectamine 2000 (LA), and benzyl alcohol (BA)
|
Mus musculus
|
Mus musculus
|
| 41 |
Inhibitor of NEDD8-activating enzyme MLN4924 effect on melanoma cell line
|
Homo sapiens
|
Homo sapiens
|
| 42 |
Expression data from mouse B16-F10 cells treated with heat shock (HS), Lipofectamine 2000 (LA), and benzyl alcohol (BA)
|
Mus musculus
|
Mus musculus
|
| 43 |
Inhibitor of NEDD8-activating enzyme MLN4924 effect on melanoma cell line
|
Homo sapiens
|
Homo sapiens
|
| 44 |
Inhibitor of NEDD8-activating enzyme MLN4924 effect on melanoma cell line
|
Homo sapiens
|
Homo sapiens
|
| 45 |
Inhibitor of NEDD8-activating enzyme MLN4924 effect on melanoma cell line
|
Homo sapiens
|
Homo sapiens
|
| 46 |
Anti-proliferative effects of continued mitogen activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma: Implications for treatment beyond disease progression
|
Homo sapiens
|
Homo sapiens
|
| 47 |
CD133 depletion effect on metastatic melanoma cell line
|
Homo sapiens
|
Homo sapiens
|
| 48 |
KINK-1, a novel small-molecule inhibitor of IKKbeta, enhances susceptibility of melanoma cells to antitumoral treatment
|
Homo sapiens
|
Homo sapiens
|
| 49 |
KINK-1, a novel small-molecule inhibitor of IKKbeta, enhances susceptibility of melanoma cells to antitumoral treatment
|
Homo sapiens
|
Homo sapiens
|
| 50 |
KINK-1, a novel small-molecule inhibitor of IKKbeta, enhances susceptibility of melanoma cells to antitumoral treatment
|
Homo sapiens
|
Homo sapiens
|
| 51 |
Analysis of genes regulated by FoxD3 in B16-F10 mouse melanoma cells
|
Mus musculus
|
Mus musculus
|
| 52 |
Hs 294T Cells Treated with Elesclomol Alone or in Combination with NAC Compared to DMSO Treated
|
Homo sapiens
|
Homo sapiens
|